G12D MUTATED KRAS
Clinical trials for G12D MUTATED KRAS explained in plain language.
Never miss a new study
Get alerted when new G12D MUTATED KRAS trials appear
Sign up with your email to follow new studies for G12D MUTATED KRAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets tough pancreatic cancer mutation
Disease control Recruiting nowThis study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …
Matched conditions: G12D MUTATED KRAS
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…
Matched conditions: G12D MUTATED KRAS
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC